DemeRx
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1951 NW 7th Ave Ste 600, Miami, Florida,...Phone Number
(786) 347-3500Website
www.demerx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About DemeRx
DemeRx is a clinical-stage biopharmaceutical company focused on developing innovative treatments for alcohol use disorder (AUD) through its investigational therapy DMX-1001, an oral form of noribogaine. The company aims to transform addiction therapeutics by addressing the underlying neuroplasticity issues that traditional treatments often overlook. With a commitment to improving outcomes for individuals battling substance use disorders, DemeRx is dedicated to advancing its research and clinical trials. The company targets a significant population, as AUD affects over 29 million people in the U.S.Explore more
DemeRx Org Chart
BA
Lead Consultant Psychiatry
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DemeRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on DemeRx recently announced quarterly report
Product Launch: Get notified when DemeRx launches new products
DemeRx, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once DemeRx has new funding data
Check out if DemeRx is spiking on competitors!
Check if DemeRx has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at DemeRx
Click to see if DemeRx had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to DemeRx
Compare insights from companies similar to DemeRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
DemeRx
<$5M
11-50
Private
-
2020
PG
Pascal GoldschmidtDirector, Lead Consultant Cardiology, Board Member
Company Profile Activity
Activity Insights
DemeRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
DemeRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about DemeRx.
DemeRx Tech Stack
A closer look at the technologies used by DemeRx
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
DemeRx News & Media
DemeRx NB Inc. Advances Study for Alcohol Use Disorder Treatment
Noribogaine is a Potential Breakthrough Treatment for Alcoholism Harnessing Benefits of Ibogaine While Removing Psychedelic Side Effects MIAMI, FLORIDA, USA, August 8, 2024 /EINPresswire.com/ -- DemeRx NB, Inc., a company dedicated to developing new …DemeRx Inc. to Present at Wonderland Miami by Microdose
Florida--(Newsfile Corp. - November 6, 2021) - DemeRx IB, Inc. ("DemeRx"), a company focused on developing ibogaine for the treatment of opioid use disorder (OUD), will be presenting at Wonderland Miami Conference by Microdose on November 9th, 2021, The Evolution of Ibogaine Treatment. DemeRx in joint partnership with atai Life Sciences received MHRA approval for DMX-1002 (Ibogaine) to commence a Phase 1/2a study as the first clinical trial in Opioid Use Disorder. ...DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced that the first subjects have been dosed in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002). The trial has commenced enrollment and dosing of recreational drug users and healthy volunteers in the Phase 1 segment of the study atDemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK
NEW YORK, March 10, 2021 /PRNewswire/ -- DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DemeRx
Sign Up For FreeTo access detailed company insights
DemeRx is a clinical-stage biopharmaceutical company focused on developing innovative treatments for alcohol use disorder (AUD) through its investigational therapy DMX-1001, an oral form of noribogaine. The company aims to transform addiction therapeutics by addressing the underlying neuroplasticity issues that traditional treatments often overlook... Read More
